MFDS Approves 'Badanem Tablets,' a New Drug for Treating Anemia in Chronic Kidney Disease Patients
The Ministry of Food and Drug Safety announced on the 14th that it has approved two dosages (150 mg and 300 mg) of Mitsubishi Tanabe Pharma Korea's new anemia treatment drug for chronic kidney disease patients, 'Badanem Tablets (Badadustat)'.
Badanem Tablets are used to treat anemia in adult patients with chronic kidney disease undergoing hemodialysis. The drug works by inhibiting prolyl hydroxylase, which degrades hypoxia-inducible factor (HIF), thereby promoting red blood cell production. HIF is a protein induced in response to insufficient oxygen supply to cells.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "If Both Spouses Work There, How Much Would They Make?" "They Earn More Than Me, and I'm a Doctor"... Envy Erupts Over Samsung Electronics' Bonus
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The Ministry of Food and Drug Safety stated, "We will continue to do our best to ensure that treatments with confirmed safety and efficacy are supplied promptly based on regulatory science expertise, thereby expanding treatment opportunities for patients."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
